Skip to Content

Executive Leadership

Executive Leadership

Al Altomari

Alfred Altomari
Chairman and Chief Executive Officer and Director

Mr. Altomari has has served as our Chairman of the Board and Chief Executive Officer since October 2016 and has been a member of our Board of Directors since February 2004. Mr. Altomari served as President and Chief Executive Officer from 2010 to 2016. Previously Mr. Altomari served as Agile's Executive Chairman from 2004 to 2010. From 2003 to 2008, Mr. Altomari held multiple senior management positions at Barrier Therapeutics, Inc., including Chief Commercial Officer, Chief Operating Officer, and Chief Executive Officer. In 2008, in his role as Chief Executive Officer and as a member of Barrier's Board of Directors, Mr. Altomari completed the successful sale of Barrier to Stiefel Laboratories, which was subsequently acquired by GlaxoSmithKline plc. From 1982 to 2003, Mr. Altomari held numerous executive roles in general management, commercial operations, business development, product launch preparation, and finance with Johnson & Johnson. Mr. Altomari also serves on the Board of Directors of Insmed Inc. He previously served on the Board of Directors of Recro Pharm, Inc. and  Baudax Bio. Mr. Altomari received an M.B.A. from Rider University and his B.S. from Drexel University. He currently serves as a Trustee of Drexel University and is on LeBow College of Business Advisory Board and the Board of the Charles D. Close School of Entrepreneurship at Drexel University.

    Scott M. Coiante

    Scott Coiante
    Chief Financial Officer

    Mr. Coiante has been our Chief Financial Officer since August of 2023.  He joined the Company from Aprea Therapeutics, Inc. where he served as the Chief Financial Officer from August 2019 until January 2023 and remained as an employee through March 31, 2023. Prior to joining Aprea Therapeutics, Inc., Mr. Coiante served as our Senior Vice President and Chief Financial Officer from 2010 to August 2019. From 2002 to 2010, Mr. Coiante was Vice President of Finance and Treasurer at Medarex, Inc., formerly a NASDAQ listed biotech company that was acquired in 2009 by Bristol Myers Squibb. From 1989 to 2002, Mr. Coiante held management positions of increasing responsibilities at Ernst & Young LLP. Mr. Coiante received a B.S. in Accounting from Villanova University.

      Robert G. Conway

      Chief Corporate Planning and Supply Chain Officer
      Mr. Conway has been our Chief Corporate Planning and Supply Chain Officer since November 2022. Prior to that, he served in various roles for the Company, including Senior Vice President, Enterprise Planning and Information Management; Senior Vice President of Operations; and Chief Development Officer and Vice President of Operations. Mr. Conway has over 30 years of practice in U.S. and international operations with an extensive background in the medical device, pharmaceutical and consumer products industries. Mr. Conway has also previously served as Principal of R. G. Conway and Associates, an independent engineering and project management consulting firm. Prior to consulting in 1997, Mr. Conway began his career in healthcare with Johnson & Johnson and later joined a Johnson & Johnson supported venture-backed medical device company operating as President and Chief Operating Officer. Mr. Conway holds a B.S. degree in Mechanical Engineering from New Jersey Institute of Technology.

        Geoffrey P. Gilmore

        Geoffrey P. Gilmore
        Chief Administrative Officer
        Mr. Gilmore has been our Chief Administrative Officer since November 2022. Prior to that, he served as the Company’s General Counsel since August 2014. From 2012 to April 2016, Mr. Gilmore was a principal of Life Sciences Advisory Services, providing consulting services to the pharmaceutical and life science industries. He served as Senior Vice President, General Counsel and Corporate Secretary of Amicus Therapeutics, Inc., a public bio-pharmaceutical company, from 2008 to 2012. Prior to joining Amicus, Mr. Gilmore spent 10 years at Bristol-Myers Squibb where he held roles of increasing responsibility in the legal department with the Commercial, Intellectual Property, and R&D legal groups, served in the Office of the Corporate Secretary and then reported to the General Counsel as Vice-President and Senior Counsel, Corporate Securities. Mr. Gilmore began his legal career in the business and finance groups at Philadelphia based law firms, Ballard Spahr LLP and Montgomery McCracken Walker & Rhoads LLP. Mr. Gilmore received his B.A. degree from Franklin and Marshall College, and his J.D. from the University of Michigan Law School.

          Paul Korner, MD, MBA

          Chief Medical Officer

          Dr. Korner has been our Chief Medical Officer since August 2020. He has served in various leadership positions of increasing responsibility at several global companies focused on female reproductive health, including Solvay Pharmaceuticals, Wyeth Research, Bayer, and Ferring Pharmaceuticals. Dr. Korner has led more than 50 clinical trials that include multiple engagements with the U.S. Food and Drug Administration, European Medicines Agency, Pharmaceuticals and Medical Devices Agency in Japan, and Health Canada. Most recently Dr. Korner brought his clinical and development acumen to the gene therapy space as a Senior Vice President of Clinical Development & Medical Affairs at Axovant Gene Therapies, Ltd. He currently serves on the Laidlaw Venture Partners Scientific Advisory Board and the Board of Directors of Voltron Therapeutics as an Independent Director. Dr. Korner received his MD from the Stritch School of Medicine at Loyola University and also holds an MBA from the Michael J. Coles College of Business at Kennesaw State University.

            Amy Welsh

            Chief Commercial Officer
            Ms. Welsh has been our Chief Commercial Officer since November 2022. Prior to that, she served as the Company’s Vice President of Marketing since May 2020. She brings over 25 years of industry marketing experience to Agile with a proven track record in product launch and lifecycle management. Prior to joining Agile, Ms. Welsh served for 3 years as the Vice President of Marketing at Antares Pharma Inc., a public specialty pharmaceutical company, where she oversaw the launch of its flagship brand XYOSTED, as well as the commercialization of products, strategic planning of developmental assets, as well as new M&A opportunities. Before Antares, she spent over eight years at AstraZeneca in brand management and marketing roles of increasing responsibility. Ms. Welsh also brings perspective and experience from her time working at a digital advertising agency dedicated to serving the life sciences industry. Ms. Welsh earned a dual B.A degree in Marketing Communications and English Literature from LaSalle University.

              Kimberly Whelan

              Vice President, Policy, Advocacy and Market Access

              Ms. Whelan joined Agile Therapeutics in December 2019. She brings over 35 years of experience in various capacities in the healthcare industry, including finance, sales, marketing, business development, health policy and market access.  Immediately prior to joining Agile Therapeutics, Kimberly worked on Strategic Initiatives at the Health Management Academy, which is a peer learning company that convenes C-Suite executives from the top-100 US Health Systems and industry to work on solving key healthcare challenges.  After beginning her career in public accounting, Kimberly joined the finance team at Johnson & Johnson.  After her experience in finance, she moved to the commercial side of the business where she spent her most of her career in diverse leadership roles, including:  Sales, where she was responsible for delivering results both individually and as a leader;  Marketing, where she was responsible for creating and executing successful pre-launch, launch and post launch marketing strategies within multiple therapeutic areas;  Business Development, where she completed assessments and recommendations for mergers, licensing, and acquisitions that aligned with the therapeutic area strategic plans. Most recently, Kimberly led Market Access efforts, where she developed strategies for product reimbursement and supported key account directors in identifying potential policy issues related to key therapeutic areas of interest and developing long-term strategies to ensure patient access.  She has worked in both the pharmaceutical and medical device businesses in her career.  Ms. Whelan received a B.S. in Computer Science and Accounting from LaSalle University.